Hints and tips:
Related Special Reports
...The S&P biotech index is trading about 50 per cent below its peak in February 2021....
...Alba Group and S Developments did not respond to a request for comment. A lawyer for Burke did not provide any comment for publication....
...If ARD-101’s phase 3 trial is successful, it would also bring to market by 2026 a treatment for Prader-Willi syndrome, which causes weight gain since sufferers never feel full....
...involves the use of plants for pharmaceuticals and cosmetics....
...Like many European pharmaceutical companies, it makes a large proportion of sales in the US....
...Two weeks after losing its most prominent brand ambassador, the weight-loss group lost another fifth of its value on reports its lenders were preparing for debt talks after S&P cut its credit rating to a...
...The US pharmaceutical company — whose shares are up 130 per cent over the past year and is now a top-10 S&P 500 stock — chose the week of the Oscars to launch an advert called “Big Night”....
...Children in Cameroon will begin receiving malaria vaccines as part of a rollout of the medicine developed by UK pharmaceutical company GSK in up to 12 countries across sub-Saharan Africa....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...If Covid-19’s reproduction or R number — the expected number of people one infected person will infect in a susceptible population — is 1-2, for measles it is 12-18....
...The closely followed SPDR S&P Biotech ETF tumbled almost two-thirds from its 2021 high, weighed down by rising interest rates and a backlash to pandemic-era over-optimism about new drugs....
...Novartis notched a 10 per cent increase in sales in 2023 as strong performance for its heart and arthritis medicines helped Europe’s second-largest pharmaceuticals company beat its guidance for the year....
...The tribunal ruled that the largest company in the FTSE 100 discriminated against James Muir — a leading scientist who had been developing the pharmaceutical company’s drug, Truqap — on the basis of a disability...
...Large drugmakers have also underperformed, with the S&P 500 pharmaceutical sub-index heading for its worst performance relative to the broader S&P 500 in at least 20 years....
...A once-popular fund, the SPDR S&P Biotech ETF, has lost 14 per cent of its value this year, falling 60 per cent from its highs....
...Commiserations to 2022’s winner Tyler Yarnell, who in 2023 came third last with a portfolio betting on Canadian oil companies — and a short position on Carvana....
...It has a range of defensive and growth stocks, including banks, pharmaceuticals and luxury retailers....
...Worth noting is that although the Novo Nordisk Foundation owns about 28 per cent of the shares in the pharmaceutical company Novo Nordisk A/S, the two organisations are individual entities with separate...
...Meanwhile, vaccine makers whose stocks were winners of the early pandemic period such as Pfizer, BioNTech, Moderna and Johnson & Johnson have been among the worst-performers in a year when the S&P 500 approached...
...Declining tax rates accounted for a hefty 22 per cent of the profit growth of S&P 500 non-financial groups in the three decades to 2019, a study by the Federal Reserve’s Michael Smolyansky has shown....
...R21’s approval would help meet “huge” demand for malaria shots, WHO officials said....
...The shift towards health has also offered Nestlé a hedge against a possible backlash against unhealthy foods....
...But it lags far behind the US, where S&P 500 company chiefs earned on average $16.7mn (then £13.6mn) in 2022....
...The Russell 2000 index has risen 24 per cent since the beginning of 2020, lagging behind the S&P 500’s more than 60 per cent gain over the same period. Read the full story. 4....
...But he appeals to swaths of America that are hostile to the pharmaceutical industry....
International Edition